post

ON SPOTLIGHT OPTOMED OY SELECTED TO RECEIVE GRANT IN TECHEMERGE PROGRAM

Oulu, Finland, January 13, 2017 – Optomed Oy, Finland based and the world’s fastest growing retinal camera company today announced that it reached the final round in TechEmerge, a World Bank Group initiative. TechEmerge is a first of its kind matchmaking program for proven technology companies around the world that are looking to grow their business in emerging markets. The inaugural program was launched for healthcare in India. 

“We at Optomed are very excited to be selected to receive grant funding under the TechEmerge program. Being among the 16 finalists from 330 companies who applied, this is a great acknowledgement to our technology. Our focus is on providing cost efficient, reliable and easy-to-use ophthalmic imaging systems without compromising image quality. The TechEmerge grant will support our pilot project in India, and we truly appreciate IFC’s decision to award a grant for our project as well as Tekes’s support since the beginning of the project,” says Mr. Kristo Kivilaakso, Executive Vice President, Sales and Marketing of Optomed.

“This is a great opportunity to bring Optomed’s innovative products to the Indian market through one of the reputed eye care institutions Eye-Q hospitals with the help of IFC’s TechEmerge grant. This pilot enables us to understand how we fit into medium segment clinics in Tier-2 cities and also to validate our technology to an existing technology,” Mr. Udaya Malla, Indian Country Manager of Optomed continues.

“On behalf of Eye-Q Hospitals, I would like to congratulate Optomed for bringing this low-cost and truly portable Smartscope FA camera to ophthalmology. FA images captured during demo sessions were excellent. This would provide us tremendous support in fulfilling our dream of taking affordable high quality eye care to Tier-2 and Tier-3 cities of India. The ongoing pilot with Optomed would help clinicians repose faith in device and would also validate the clinical utility of FA module in real life settings,” says Dr. Deependra.V.Singh, Director, Retina Services of Eye-Q Super Speciality Eye Hospitals.

About Optomed
Optomed Oy is an innovative Finnish medical technology company that specializes in retinal imaging devices and solutions. The product portfolio consists of unique digital imaging instruments that provide retinal and eye anterior imaging with one portable device. Optomed’s key product is Smartscope® PRO, a modular hand-held retinal camera for screening and diagnosis of various eye diseases, such as diabetic retinopathy, glaucoma and AMD.  It is the smallest product on the market with high image quality which fulfills international ISO 10940 fundus camera standard requirements. Optomed’s products are being used by private clinics, public hospitals, non-government organizations and charities around the world, and are registered and marketed in all major markets: Europe, USA, China, Russia, Japan, Korea, India and Brazil. Further information: www.optomed.com.

About Eye-Q Super Speciality Eye Hospitals
Eye-Q is a chain of super speciality eye hospitals committed to providing high-quality and affordable eye-care services across India.  Eye-Q, an ISO 9001-2000 registered organization, has acquired venture funding from SONG Investment Advisors, Helion Venture Partners Nexus Venture Partners & International Finance corporation (IFC). The super-specialty hospitals offer a complete range of medical and surgical eye care and optical services like cataract services, refractive services, retina services, glaucoma, paediatric oculoplasty, visual aid services to patients of all age-group through exceptional array of preventive and corrective procedures and cutting-edge practices. For more information, log onto https://www.eyeqindia.com/.

About International Finance Corporation (IFC)
IFC, a member of the World Bank Group, is the largest global development institution focused on the private sector in emerging markets. Working with 2,000 businesses worldwide, we use our six decades of experience to create opportunity where it’s needed most. In FY16, our long-term investments in developing countries rose to nearly $19 billion, leveraging our capital, expertise and influence to help the private sector end extreme poverty and boost shared prosperity. IFC’s Venture Capital (VC) group invests in technology-driven venture/growth companies with high impact potential, both local businesses based in emerging markets, as well as increasingly in US/European companies with business solutions geared towards emerging markets. For more information, visit www.ifc.org. For more information about the TechEmerge program visit www.techemerge.org.

For further information:
Mr. Kristo Kivilaakso
Executive Vice President, Sales and Marketing
Optomed Oy
Tel: +358 40 554 5253
E-mail: kristo.kivilaakso@optomed.com